Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2012

View Archived Issues

Polypeptide confers neuroprotection after stroke

New E-NPP 2 inhibitors patented by Ono Pharmaceutical

Actelion Pharmceuticals discloses novel prostanoid DP2 receptor antagonists

U.K. universities present new dust mite peptidase 1 inhibitors

Sanofi synthesizes new fibroblast growth factor receptor antagonists

New nematode serpin-based thrombin inhibitors discovered

Third arGEN-X candidate therapeutic advances into preclinical development

Astrogenetix and NASA enter agreement for drug research in space

Eribulin mesilate added to chemotherapy in patients with bladder cancer

VistaGen Therapeutics and Cato enter drug rescue agreement

Bayer and Almirall to copromote oral anticoagulant in Spain

AVI BioPharma reports data from phase I trials of AVI-6002 and AVI-6003

DMC recommends LibiGel safety study continue as planned

Titan Pharmaceuticals reports results from probuphine trial

Potassium channel antagonist improves motor function in model of stroke

Gene therapy succesfully readministered to patients with Leber's congenital amaurosis

Jubilant and Endo Pharmaceuticals nominate anticancer candidate

Tekmira Ebola fever therapy enters clinic

GlobeImmune begins phase I trial of new cancer vaccine

Pfizer and ICAgen identify new candidate analgesics

Metal-dependent inhibitors of LDL-PLA2 identified

Outcome of FDA advisory committee meeting on Qutenza sNDA reported

Vernalis and Tris Pharma enter licensing agreement

Genmab achieves second milestone in CNS disorder collaboration

Phase I trial of Patrys anticancer antibody meets primary endpoint

FDA advisory committee issues vote on Dacogen sNDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.